Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Inclusion Criteria: * Adults over the age of 18 with malignant melanoma. * HLA-A2.1 positive and express MART-1, as assessed by either RT-PCR or by immunohistochemistry * Tumor stages T3N0M0 or greater are eligible for this trial according to the following: 1. I (\<.75 to 1.5 mm or Clark level III-T1-2N0M0-)-not eligible 2. II (1.5 to 4 mm or level IV-T3N0M0-)-eligible 3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)-eligible 4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)-eligible 5. Relapsed melanoma-eligible * Patients previously treated with any form of therapy for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous treatment was completed \>30 days prior to enrollment * Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment * Karnofsky Performance Status greater than or equal to 70 percent * No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease * No previous evidence of opportunistic infection * A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy * Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): 1. Hemoglobin \>9.0 g/dl 2. Platelets \> 100000/mm3 3. WBC \> 3000/mm3 4. Absolute Neutrophil Count \> 1000/mm3 * Positive skin test to common antigens (tetanus and candida) * Ability to give informed consent Exclusion Criteria: * Lactating females and females of child-bearing potential must have negative serum beta-HCG pregnancy test * Acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy. Acute therapy must have been completed within 14 days of prior to study treatment * HIV-infected patients * Acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk * Patients with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents used in this study) * Patients with organ allografts * Uncontrolled CNS metastasis. Patients with CNS metastasis will be eligible if they have received CNS irradiation to control local tumor growth